Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 1
1990 1
1991 1
1992 2
1994 1
1996 2
1998 1
1999 4
2000 2
2001 4
2002 5
2003 2
2004 2
2005 1
2006 2
2007 6
2008 3
2009 5
2010 1
2011 1
2012 2
2013 4
2014 4
2015 4
2016 3
2017 4
2018 12
2019 8
2020 12
2021 12
2022 14
2023 12
2024 18
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease.
Shen Y, Timsina J, Heo G, Beric A, Ali M, Wang C, Yang C, Wang Y, Western D, Liu M, Gorijala P, Budde J, Do A, Liu H, Gordon B, Llibre-Guerra JJ, Joseph-Mathurin N, Perrin RJ, Maschi D, Wyss-Coray T, Pastor P, Renton AE, Surace EI, Johnson ECB, Levey AI, Alvarez I, Levin J, Ringman JM, Allegri RF, Seyfried N, Day GS, Wu Q, Fernández MV, Tarawneh R, McDade E, Morris JC, Bateman RJ, Goate A; Dominantly Inherited Alzheimer Network; Ibanez L, Sung YJ, Cruchaga C. Shen Y, et al. Cell. 2024 Oct 31;187(22):6309-6326.e15. doi: 10.1016/j.cell.2024.08.049. Epub 2024 Sep 26. Cell. 2024. PMID: 39332414 Free PMC article.
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Gray R, et al. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. JAMA Neurol. 2022. PMID: 34962574 Free PMC article. Clinical Trial.
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.
Shirzadi Z, Schultz SA, Yau WW, Joseph-Mathurin N, Fitzpatrick CD, Levin R, Kantarci K, Preboske GM, Jack CR Jr, Farlow MR, Hassenstab J, Jucker M, Morris JC, Xiong C, Karch CM, Levey AI, Gordon BA, Schofield PR, Salloway SP, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Day GS, Koeppe R, Chui HC, Berman S, Mori H, Sanchez-Valle R, Lee JH, Rosa-Neto P, Ruthirakuhan M, Wu CY, Swardfager W, Benzinger TLS, Sohrabi HR, Martins RN, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Schultz AP, Chhatwal JP; Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging Initiative. Shirzadi Z, et al. JAMA Neurol. 2023 Dec 1;80(12):1353-1363. doi: 10.1001/jamaneurol.2023.3618. JAMA Neurol. 2023. PMID: 37843849 Free PMC article.
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.
Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, Ping L, Duong DM, Epstein MP, McDade E, Barthélemy NR, Karch CM, Xiong C, Cruchaga C, Perrin RJ, Wingo AP, Wingo TS, Chhatwal JP, Day GS, Noble JM, Berman SB, Martins R, Graff-Radford NR, Schofield PR, Ikeuchi T, Mori H, Levin J, Farlow M, Lah JJ, Haass C, Jucker M, Morris JC, Benzinger TLS, Roberts BR, Bateman RJ, Fagan AM, Seyfried NT, Levey AI; Dominantly Inherited Alzheimer Network. Johnson ECB, et al. Among authors: noble jm. Nat Med. 2023 Aug;29(8):1979-1988. doi: 10.1038/s41591-023-02476-4. Epub 2023 Aug 7. Nat Med. 2023. PMID: 37550416 Free PMC article.
Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer's disease.
Hofmann A, Häsler LM, Lambert M, Kaeser SA, Gräber-Sultan S, Obermüller U, Kuder-Buletta E, la Fougere C, Laske C, Vöglein J, Levin J, Fox NC, Ryan NS, Zetterberg H, Llibre-Guerra JJ, Perrin RJ, Ibanez L, Schofield PR, Brooks WS, Day GS, Farlow MR, Allegri RF, Chrem Mendez P, Ikeuchi T, Kasuga K, Lee JH, Roh JH, Mori H, Lopera F, Bateman RJ, McDade E, Gordon BA, Chhatwal JP, Jucker M, Schultz SA; Dominantly Inherited Alzheimer Network. Hofmann A, et al. Nat Commun. 2024 Nov 18;15(1):9982. doi: 10.1038/s41467-024-52937-8. Nat Commun. 2024. PMID: 39557867 Free PMC article.
Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia.
Llibre-Guerra JJ, Fernandez MV, Joseph-Mathurin N, Bian S, Carter K, Li Y, Aschenbrenner AJ, Pottier C, Sigurdson W, McDade E, Gordon BA, Renton AE, Benzinger TLS, Ibañez L, Barthelemy N, Johnson M, Hassenstab J, Wang G, Goate AM, Western D, Wang C, Hobbs D, Daniels A, Karch C, Morris JC, Cruchaga C, Johnson ECB, Bateman RJ; Dominantly Inherited Alzheimer Network. Llibre-Guerra JJ, et al. Nat Med. 2025 Apr;31(4):1267-1275. doi: 10.1038/s41591-025-03494-0. Epub 2025 Feb 10. Nat Med. 2025. PMID: 39930140
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, Farlow MR, Clifford DB, Supnet-Bell C, Santacruz AM, Aschenbrenner AJ, Hassenstab JJ, Benzinger TLS, Gordon BA, Coalier KA, Cruchaga C, Ibanez L, Perrin RJ, Xiong C, Li Y, Morris JC, Lah JJ, Berman SB, Roberson ED, van Dyck CH, Galasko D, Gauthier S, Hsiung GR, Brooks WS, Pariente J, Mummery CJ, Day GS, Ringman JM, Mendez PC, St George-Hyslop P, Fox NC, Suzuki K, Okhravi HR, Chhatwal J, Levin J, Jucker M, Sims JR, Holdridge KC, Proctor NK, Yaari R, Andersen SW, Mancini M, Llibre-Guerra J, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network–Trials Unit. Wagemann O, et al. JAMA Neurol. 2024 Jun 1;81(6):582-593. doi: 10.1001/jamaneurol.2024.0991. JAMA Neurol. 2024. PMID: 38683602 Free PMC article. Clinical Trial.
156 results